Acta Pharmacologica Sinica, Год журнала: 2024, Номер 45(6), С. 1130 - 1141
Опубликована: Янв. 9, 2024
Язык: Английский
MedComm, Год журнала: 2024, Номер 5(5)
Опубликована: Май 1, 2024
Abstract RNA modification, especially methylation, is a critical posttranscriptional process influencing cellular functions and disease progression, accounting for over 60% of all modifications. It plays significant role in metabolism, affecting processing, stability, translation, thereby modulating gene expression cell essential proliferation, survival, metastasis. Increasing studies have revealed the disruption metabolism mediated by methylation has been implicated various aspects cancer particularly metabolic reprogramming immunity. This profound implications tumor growth, metastasis, therapy response. Herein, we elucidate fundamental characteristics their impact on expression. We highlight intricate relationship between reprogramming, immunity, using well‐characterized phenomenon as framework to discuss methylation's specific roles mechanisms progression. Furthermore, explore potential targeting regulators novel approach therapy. By underscoring complex which contributes this review provides foundation developing new prognostic markers therapeutic strategies aimed at treatment.
Язык: Английский
Процитировано
17
MedComm, Год журнала: 2025, Номер 6(1)
Опубликована: Янв. 1, 2025
Abstract RNA modifications are emerging as critical cancer regulators that influence tumorigenesis and progression. Key modifications, such N6‐methyladenosine (m 6 A) 5‐methylcytosine 5 C), implicated in various cellular processes. These regulated by proteins write, erase, read modulate stability, splicing, translation, degradation. Recent studies have highlighted their roles metabolic reprogramming, signaling pathways, cell cycle control, which essential for tumor proliferation survival. Despite these scientific advances, the precise mechanisms affect remain inadequately understood. This review comprehensively examines role play proliferation, metastasis, programmed death, including apoptosis, autophagy, ferroptosis. It explores effects on epithelial–mesenchymal transition (EMT) immune microenvironment, particularly metastasis. Furthermore, modifications’ potential therapies, conventional treatments, immunotherapy, targeted is discussed. By addressing aspects, this aims to bridge current research gaps underscore therapeutic of targeting improve treatment strategies patient outcomes.
Язык: Английский
Процитировано
1
Advanced Science, Год журнала: 2025, Номер unknown
Опубликована: Фев. 20, 2025
Abstract Drug resistance remains a major hurdle for the therapeutic efficacy of lenvatinib in hepatocellular carcinoma (HCC). However, underlying mechanisms remain largely undetermined. Unbiased proteomic screening is performed to identify potential regulators HCC. Patient‐derived organoids, patient‐derived xenograft mouse models, and DEN/CCl 4 induced HCC models are constructed evaluate effects HECTD2 both vitro vivo. found be highly expressed lenvatinib‐resistant cell lines, patient tissues, organoids xenografts. In vivo experiments demonstrated that overexpression limits response treatment. Mechanistically, functions as an E3 ubiquitin ligase KEAP1, which contributes degradation KEAP1 protein. Subsequently, KEAP1/NRF2 signaling pathway initiates antioxidative cells. Lactylation histone 3 on lysine residue 18 facilitates transcription HECTD2. Notably, PLGA‐PEG nanoparticle‐based drug delivery system synthesized, effectively targeting The NPs achieved tumor‐targeting, controlled‐release, biocompatibility, making them promising strategy mitigating resistance. This study identifies nanotherapeutic target overcoming resistance, providing theoretical basis translational application
Язык: Английский
Процитировано
1
Molecular Oncology, Год журнала: 2022, Номер 17(2), С. 195 - 229
Опубликована: Окт. 19, 2022
N 6 ‐ methyladenosine (m A) is one of the most abundant internal modifications in eukaryotic messenger RNAs (mRNAs) and non‐coding (ncRNAs). It a reversible dynamic RNA modification that has been observed both coding segments untranslated regions. Studies indicate m A play important roles translation, splicing, export, degradation ncRNA processing control. In this review, we focus on profiles biological functions methylation mRNAs ncRNAs. The its potential cancer development are discussed. Moreover, discuss possibility serving as biomarkers for diagnosis targets therapy.
Язык: Английский
Процитировано
30
Cancer Gene Therapy, Год журнала: 2022, Номер 30(1), С. 163 - 171
Опубликована: Сен. 20, 2022
Язык: Английский
Процитировано
29
Biomedicine & Pharmacotherapy, Год журнала: 2023, Номер 165, С. 115104 - 115104
Опубликована: Июнь 30, 2023
Hepatocellular carcinoma (HCC) is the second most lethal cancer and a leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) significantly improved prognosis HCC; however, therapeutic response remains unsatisfactory in substantial proportion patients or needs to be further responders. Herein, other methods immunotherapy, including vaccine-based adoptive cell therapy, cytokine delivery, kynurenine pathway inhibition, gene have been adopted clinical trials. Although results were not encouraging enough expedite their marketing. A major human genome transcribed into non-coding RNAs (ncRNAs). Preclinical studies extensively investigated roles ncRNAs different aspects HCC biology. cells reprogram expression pattern numerous decrease immunogenicity HCC, exhaust cytotoxic anti-cancer function CD8 + T cells, natural killer (NK) dendritic (DCs), M1 macrophages, promote immunosuppressive Reg M2 myeloid-derived suppressor (MDSCs). Mechanistically, recruit interact with immune thereby regulating checkpoints, functional receptors enzymes, inflammatory anti-inflammatory cytokines. Interestingly, prediction models based on tissue even serum levels could predict immunotherapy HCC. Moreover, markedly potentiated efficacy ICIs murine This review article first discusses recent advances then dissects involvement potential application
Язык: Английский
Процитировано
20
Cellular Signalling, Год журнала: 2024, Номер 117, С. 111076 - 111076
Опубликована: Фев. 2, 2024
Язык: Английский
Процитировано
7
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Год журнала: 2023, Номер 1878(3), С. 188873 - 188873
Опубликована: Фев. 25, 2023
Язык: Английский
Процитировано
16
Critical Reviews in Oncology/Hematology, Год журнала: 2024, Номер 196, С. 104312 - 104312
Опубликована: Фев. 28, 2024
Язык: Английский
Процитировано
6
Non-coding RNA Research, Год журнала: 2024, Номер 9(3), С. 970 - 994
Опубликована: Май 5, 2024
Cancer cells exhibit altered metabolic pathways, prominently featuring enhanced glycolytic activity to sustain their rapid growth and proliferation. Dysregulation of glycolysis is a well-established hallmark cancer contributes tumor progression resistance therapy. Increased supplies the energy necessary for increased proliferation creates an acidic milieu, which in turn encourages cells' infiltration, metastasis, chemoresistance. Circular RNAs (circRNAs) have emerged as pivotal players diverse biological processes, including development reprogramming. The interplay between circRNAs explored, illuminating how regulate key glycolysis-associated genes enzymes, thereby influencing profiles. In this overview, we highlight mechanisms by enzymes modulate glycolysis. addition, discuss clinical implications dysregulated glycolysis, potential use diagnostic prognostic biomarkers. All all, provide most recent findings on operate at molecular level control various types cancer, hepatocellular carcinoma (HCC), prostate (PCa), colorectal (CRC), cervical (CC), glioma, non-small cell lung (NSCLC), breast gastric (GC). conclusion, review provides comprehensive overview significance shedding light intricate roles presenting innovative therapeutic avenues.
Язык: Английский
Процитировано
6